Five studies published between 2009 and 2011 are reviewed that importantly inform stroke prevention for patients with atrial fibrillation (AF) or with cervical carotid artery stenosis. Two large, phase III randomized trials tested novel oral anticoagulants for stroke prevention in patients with AF: the direct thrombin inhibitor dabigatran 150 mg twice daily was superior to adjusted-dose warfarin (RE-LY trial) and the direct factor Xa inhibitor apixaban was far superior to aspirin in patients deemed unsuitable for warfarin (AVERROES trial). For both novel anticoagulants, major bleeding rates were similar to the comparator treatment. Clopidogrel plus aspirin was more efficacious than aspirin alone for prevention of stroke in patients with AF deemed unsuitable for warfarin, but major bleeding was significantly increased with dual antiplatelet therapy (ACTIVE A trial). Two large randomized trials (CREST, ICSS) provide the best available data on the short-term risks of carotid artery stenting vs. endarterectomy. In both trials, periprocedural stroke was more frequent with stenting than with endarterectomy, but the increased risk was largely confined to patients >70 years old. For younger patients, periprocedural risks were comparable with stenting or endarterectomy, but long-term outcomes are required to assess the relative merits of the two procedures.
Introduction
We review our choices for the "top 10" studies published from 2009 to 2011 that influence our clinical management of patients with stroke and threatened stroke (TABLE 1).
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Part I summarized 4 clinical trials concerned with management of acute stroke plus the first randomized trial assessing value of percutaneous closure of a patent foramen ovale (PFO) for stroke prevention. 12 Here we consider 3 recent trials of antithrombotic drugs to prevent stroke in patients with atrial fibrillation (AF) and 2 new trials comparing carotid artery stenting with endarterectomy.
By way of disclosure, one of us (RGH) served on the stroke advisory and operations committees of the AVERROES trial (Apixaban versus Acetylsalicylic Acid to Prevent Strokes) 8 and of the ACTIVE A trial (Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events). 7 6. Novel oral direct thrombin inhibitor dabigatran is as good or better than warfarin for stroke prevention in patients with atrial fibrillation Vitamin K antagonists, such as warfarin, have been the standard oral anticoagulants for more than 50 years, but the need for anticoagulation monitoring, frequent dosage adjustments, multiple drug inter actions, and a relatively narrow therapeutic window have spurred the development of new oral anticoagulants that work by different mechanisms.
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In the RE-LY trial (Randomized Evaluation of Long-term Anticoagulant Therapy), 18,113 AF patients with at least 1 additional stroke risk factor were randomly assigned to dabigatran 110 mg twice daily, dabigatran 150 mg twice daily, or adjusted-dose warfarin (target inter national normalized ratio [INR] 2-3) and followed for a mean of 2 years. 6 The 2 dabigatran dosages were administered double-blind, with warfarin given open--label. The trial was carried out at 951 sites in 44
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What's new in stroke? The top 10 studies of [2009] [2010] [2011] Should dabigatran replace adjusted-dose warfarin for antithrombotic prophylaxis for patients with AF? This complex issue has several caveats. 15, 16 Dabigatran has important drug inter actions with P-glycoprotein inhibitors such as verapamil, amiodarone, and quinidine, and the clinical importance of drug inter actions is often not fully evident in selected participants in randomized trials. There is currently no accepted method to emergently reverse the anticoagulant effects of dabigatran in case of serious hemo rrhage, although it has a relatively short half-life (averaging 12 hours) and can be partially removed by hemo dialysis. It has been estimated that the effects of warfarin and dabigatran on preventing stroke in AF are about equal when the time in therapeutic range for warfarin is >70%, 17 but this level of warfarin anticoagulation control is infrequently achieved in clinical practice. From one editorialist: "... patients already taking warfarin with excellent INR control have little to gain by switching to dabigatran. In contrast, many other patients who have AF and at least one other risk factor for stroke countries between 2005 and 2009. Average participant age was 71 years, 64% were men, half had previously used warfarin, 20% had prior stroke/ transient ischemic attack (TIA), and 20% took aspirin (<100 mg daily) during the course of the trial. The time-in-therapeutic range for warfarin assigned patients averaged 64%. 6, 14 Dabigatran 150 mg twice daily was superior to adjusted-dose warfarin for the outcomes of all stroke or systemic embolism, of all stroke, and of all-cause mortality, and was associated with a similar risk of major hemo rrhage (TABLE 2) . Dabigatran 110 mg twice daily was associated with trends toward lower rates for these events compared with warfarin (not statistically different), but with a significantly lower rate of major hemo rrhage (TABLE 2) . Intracranial hemo rrhage, the most feared complication of anticoagulation of elderly patients, was substantially and significantly lower with both dabigatran dosages. No serious hepatotoxicity was reported, but dyspepsia was twice as frequent in those assigned to dabigatran (TABLE 2).   TABLE 1 The top 10 stroke studies of 2009-2011 1. Pooled analysis of 8 randomized trials shows substantial benefit of i.v. tPA given 3 to 4.5 hours after stroke onset. 2. Blood pressure lowering with candesartan may be harmful within the first days after acute stroke (SCAST). 2 3. Thigh-length graduated compression stockings do not reduce venous thromboembolism in patients with acute stroke (CLOTS 1). 3 4. Endovascular coiling is as good as neurosurgical clipping in the long-term for small, ruptured intracranial aneurysms (ISAT). 6. Novel oral direct thrombin inhibitor dabigatran is as good or better than warfarin for stroke prevention in patients with AF (RE-LY). 6 7. Clopidogrel plus aspirin is superior to aspirin alone for preventing stroke, but with increased bleeding, in AF patients deemed unsuitable for warfarin (ACTIVE A) 7 8. Novel oral direct factor Xa inhibitor, apixaban, is superior to aspirin for AF patients deemed unsuitable for warfarin (AVERROES). 8 9. Complication rates of carotid stenting and carotid endarterectomy are equal (CREST). 9 10. Carotid stenting has a higher complication rate than carotid endarterectomy (ICSS and pooled analysis of 3 European trials).
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Abbreviations: AF -atrial fibrillation, i.v. tPA -intravenous tissue plasminogen activator, PFO -patent foramen ovale a the prespecified primary outcome b stroke included ischemic strokes and primary intracerebral hemo rrhages; intracranial hemo rrhages included primary intracerebral hemo rrhages, subdural hematomas, and subarachnoid hemo rrhages c P <0.01 compared with warfarin d P <0.01 comparing the two dabigatran dosages e P = 0.05 vs. warfarin
Abbreviations: CNS -central nervous system
In the companion ACTIVE W trial, combination antiplatelet therapy was substantially less efficacious than adjusted-dose warfarin in patients eligible for anticoagulation. 20 In summary, ACTIVE A demonstrated that combination antiplatelet therapy traded a reduction in all stroke for a similar absolute increase in major (mostly gastrointestinal) hemo rrhage. The use of dual antiplatelet therapy for AF patients who cannot take warfarin but who are not at high bleeding risk has been approved by the European Medicines Agency, but it has not yet been considered by the European Stroke Organisation. Gastroprotective therapy with a proton-pump inhibitor (e.g., pantoprazol among many others) is recommended for patients taking antiplatelet therapy who are at special risk for upper gastrointestinal bleeding, including those receiving dual antiplatelet therapy. 21 
Novel oral direct factor Xa inhibitor, apixaban, is superior to aspirin for stroke prevention in patients with atrial fibrillation deemed unsuitable for warfarin
For the millions of AF patients who cannot or will not take adjusted-dose oral vitamin K antagonists for stroke prevention, there has been an unmet need for well-tolerated, easy-to-administer, and safe antithrombotic prophylaxis that is more efficacious than aspirin for stroke prevention. While ACTIVE A demonstrated the combination of clopidogrel plus aspirin to be superior to aspirin alone, the increased bleeding associated with dual antiplatelet therapy lessens enthusiasm for combination antiplatelet therapy. Apixaban, a novel oral selective, reversible, direct factor Xa inhibitor, was compared with aspirin in the phase III randomized AVERROES trial involving 5999 AF patients with at least 1 additional stroke risk factor and who were not deemed candidates for warfarin (40% had previously received a vitamin K antagonist).
8 Participants were assigned double-blind to apixaban 5 mg twice daily (2.5 mg twice daily in selected patients) vs. once daily aspirin (permitted dose range 81-325 mg daily) at 522 inter national sites between 2007 and 2010. Salient exclusion criteria were recent serious bleeding, active peptic ulcer disease, and severe renal insufficiency could benefit from dabigatran." 18 A recent American Heart Association/American College of Cardiology practice guideline endorsed dabigatran as an alternative to warfarin for AF patients. 19 Dabigatran has been approved by the European Medicines Agency for prevention of stroke in AF patients.
7. Clopidogrel plus aspirin is superior to aspirin alone for preventing stroke, but with increased bleeding, in atrial fibrillation patients deemed unsuitable for warfarin In AF patients deemed unsuitable for warfarin, the ACTIVE A investigators compared clopidogrel 75 mg daily plus aspirin (75-100 mg daily) with aspirin alone in a double-blinded randomized trials involving 7554 patients with at least 1 additional stroke risk factor entered from 561 centers in 33 countries (33% of participants were from Eastern Europe) between 2003 and 2008. 7 Reasons participants were deemed unsuitable for warfarin were an unacceptable bleeding risk if anticoagulated (e.g., predisposition to falling with head trauma, regular use of nonsteriodal anti--inflammatory drugs, uncontrolled hypertension, prior serious bleeding with warfarin) (23%), patient preference (26%), and physician recommendation based on the estimated balance of benefit/risk (inability to comply with INR monitoring, falling risk, alcohol habituation) (50%). Patients with high bleeding risk were excluded: active peptic ulcer disease within 6 months, prior intracranial hemo rrhage, thrombocytopenia, ongoing alcohol abuse. Mean participant age was 71 years, 58% were men, 13% had prior stroke/TIA, and the average follow-up was 3.6 years.
All stroke (ischemic and hemo rrhagic) was reduced by 28% (P <0.001) by dual antiplatelet therapy, but major hemo rrhage was increased by 57% (P <0.001) (TABLE 3). Considering absolute rates, a 0.9% per reduction in all stroke (and 0.5% per year reduction in disabling/fatal stroke) was offset by a 0.7% increase in major hemo rrhage. For the 992 participants with prior stroke/TIA (i.e., the highest risk for stroke), the stroke rate was 6.3%/y on aspirin and 4.5%/y on dual antiplatelet therapy (relative risk reduction 28%, P = 0.05, number-needed-to-treat for 1 year with dual antiplatelet therapy to prevent 1 stroke of 55). The primary outcome was the composite of ischemic stroke, myocardial infarction, and all deaths within 30 days plus ipsilateral ischemic strokes up to 4 years post-procedure (the mean follow-up was 2.5 years). About half of participants (53%) had symptomatic carotid artery stenosis ≥50%, with the remainder asymptomatic stenosis ≥60%; overall, 86% of participants had ≥70% stenosis. A single type of stent and embolic protection device was used (RX-ACCULINK and RX-ACCUNET, Abbott Vascular Solutions), and cerebral protection devices were employed in nearly all participants (96%). Carotid endarterectomy was performed under general anesthesia in 90% of patients, and intraoperative shunts were used in 57%. There was a rigorous "lead-in" phase to document the proficiency of those performing the procedures. The mean participant age was 69 years, 65% were men, 30% had diabetes mellitus, 26% were current tobacco smokers, and the average blood pressure at entry was 141/74 mmHg. The results of the CREST showed higher risk of perioperative myocardial infarction with endarterectomy and a higher risk of perioperative stroke with carotid stenting (TABLE 5) . Of note, many of the myocardial infarctions were clinically silent, with the diagnosis based on electrocardiogram and troponin enzyme changes, whereas all strokes were clinically manifest. The ipsilateral stroke rate was low after the first 30 days with both treatments. Considering all strokes and death at 4 years, endarterectomy was superior (TABLE 5) . There was no significant interaction of treatment effects with sex or symptom status, but there was a statistically significant inter action (P = 0.02) with age on the primary outcome: patients under age 70 tended to do better with stenting, and those over age 70 with endarterectomy.
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The CREST investigators concluded that the risk of the primary outcome composite did not differ significantly between the two inter ventions, 9 but, in our view, given the wide CI around the hazard (about 25% of apixaban is excreted by the kidneys). Mean participant age was 70 years, 59% were men, 14% had prior stroke/TIA, and 9% in both treatment arms took additional non-study aspirin during follow-up. The trial was terminated at inter im analysis after a mean follow-up of 1.1 years because of greater-than-anticipated efficacy of apixaban. 8 Strokes (including ischemic and hemo rrhagic) were sharply reduced by apixaban over aspirin (hazard ratio 0.46, 95% confidence inter val [CI] 0.33 to 0.65, P <0.001) with an absolute decrease 1.8% per year. Major bleeding was not significantly increased in those assigned apixaban (44 (1.4% per year) with apixaban vs. 39 (1.2% per year) with aspirin, hazard ratio 1.13, 95% CI 0.74 to 1.75) (TABLE 4). Permanent discontinuation of medication was less frequent in those assigned apixaban vs. aspirin (P = 0.03). There were 11 intracranial hemo rrhages with apixaban vs. 13 with aspirin. 8 The strikingly positive results of the AVERROES trial should be considered in perspective. While there was no appreciable increase in major hemo rrhage seen with apixaban over aspirin in the AVERROES trial, the CI around hazard ratio is relatively wide. Drug inter actions with apixaban, particularly with those meta bolized through the CYP450 system, have not been fully elucidated. Additional caveats that apply to any of the novel oral anticoagulants have been described. 22 Apixaban has yet not been approved by major regulatory agencies for AF patients. The ongoing companion ARISTOTLE trial (Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation) is comparing apixaban with adjusted-dose warfarin, with results anticipated in late 2011, and should contribute to a fuller picture of the role of apixaban in AF patients. 23 Preliminary results of a large randomized trial comparing another direct factor Xa inhibitor, rivaroxaban, with warfarin in AF patients reported comparable stroke rates with the two therapies. Apixaban, %/y n = 2808
Aspirin, %/y n = 2791
Hazard ratio P all first stroke (n) ischemic strokes (n) blood pressure was 146/78 mmHg at entry. Several different types of stents and cerebral protection devices (the latter was used in 72% of cases) were employed. Centers were classified as experienced or supervised, depending on whether the investigator had previously placed >50 stents and/or performed >50 endarterectomies; 12% of participants were entered at centers designated as supervised, but outcomes were similar to those at centers designated as experienced. Nondisabling stroke was the major difference in these 120-day results: 3% higher with stenting (P <0.001) (TABLE 6). In a substudy involving about 15% of participants, there was a large imbalance in new magnetic resonance imaging diffusion--positive abnormalities indicative of acute brain ischemia assessed 1 day after the procedures: 50% of 124 patients undergoing stenting vs. 17% of 104 patients undergoing endarterectomy (and not different for patients in whom cerebral protection devices were employed). 26 The 120-day stroke rates in the ICSS were higher in both treatment arms compared with the CREST, at least in part due to the symptomatic status of all ICSS participants, recognized to be associated with higher perioperative stroke rates. 9 The rate of perioperative myocardial infarction in the ICSS was only about 20% of the rate observed in the CREST ratio for the primary outcome, the study was underpowered to assess whether the procedures are equivalent within a clinically meaningful range (i.e., stenting could be 19% better or 51% worse than endarterectomy). The accompanying editorial concluded that "until more data are available, endarterectomy remains the preferred treatment for most patients with symptomatic carotid stenosis; treatment for asymptomatic stenosis remains controversial. However, given the lack of significant difference in the rate of long-term outcomes, the individualization of treatment choices is appropriate." 25 ICSS (International Carotid Stenting Study) was an inter national (50 sites in Europe, Australia, New Zealand, and Canada) randomized trial conducted between 2001 and 2009, which also compared carotid stenting with endarterectomy. 10 All participants had symptoms within 1 year (almost all were within 6 months) referable to a carotid with >50% stenosis (90% of had ≥70% stenosis). The primary outcome was disabling/fatal stroke (any arterial territory) during long-term followup, which was not reported pending additional observation, and only 120-day inter im results were provided. The mean participant age was 70 years old, 71% were men, 22% had diabetes mellitus, 23% were current tobacco smokers, and mean "stenting for symptomatic carotid stenosis should be avoided in older patients (age ≥70 years), but might be as safe as endarterectomy in younger patients." 11 Updated recommendations regarding indications for carotid stenting vs. endarterectomy from the European Stroke Organisation 28 or other major national guidelines are not available since publication of these informative recent studies. Longer-term outcomes from these recent trials, especially the durability of stenting, are awaited. Of note, a randomized trial of stenting of symptomatic intracranial stenosis was recently stopped due to an unacceptably high periprocedural stroke rate. (explained by inclusion of "silent" myocardial infarcts in the CREST). No subgroups were identified that had better results with stenting (including the absence of an age inter action). The ICSS investigators concluded that "our results are applicable to the current practice of carotid stenting" and that, pending long-term follow-up results, "carotid endarterectomy should remain the treatment of choice for patients with symptomatic carotid stenosis who are suitable for surgery." 10 The Carotid Stenting Trialists' Collaboration pooled individual participant data from 3 European randomized trials of stenting vs. endarterectomy of symptomatic patients: EVA-3S (Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis), SPACE (Stent-supported Percutaneous Angioplasty of the Carotid artery versus Endarterectomy), and the recent ICSS. 11 The two earlier trials had been criticized by some for lack of experience of those performing stenting (EVA 3S) and nonuse of cerebral protection devices (SPACE). Short-term results for 3433 randomized patients were generally consistent between all 3 trials (and also with the CREST) (fIGURE) 27 Considering any stroke or death, the 120-day risk was significantly lower with endarterectomy (6%) than with stenting (9%) (P = 0.001), but there was a statistically significant inter action with age regarding this outcome composite: the additional risk seen with stenting was confined to those ≥70 years old. The investigators concluded that Abbreviations: CAS -carotid artery stenting, CEA -carotid endarterectomy, RR -relative risk, n -number of events, N -number of patients, otherssee TABLE 5 
